In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment

다국어 초록 (Multilingual Abstract)

Tractable experimental model that accounts for inter-tumor molecular heterogeneity is a key element of anti-cancer drug development. Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors, including somatic genetic and epigenetic alterations. Previous studies showed that molecular tumor subtypes determined by transcriptome, as a comprehensive functional readout, are reproducibly observed across global patient populations irrespective of geographic and etiological variations. Here we demonstrate that transcriptomic hepatocellular carcinoma subtypes, S1 and S2, determined by our previous transcriptome meta-analysis of multiple clinical hepatocellular carcinoma cohorts, are presented in a panel of hepatoma cell lines widely used by the research community. Interestingly, cell line that resembles gene expression pattern of S3 subtype, representing less aggressive tumors, was not identified in the panel. MYC pathway-activated S2-like cell lines showed higher sensitivity to a small molecule BET bromodomain inhibitor, (+)-JQ1, which has anti-MYC activity. These results support the use of hepatoma cell lines as models to evaluate molecular subtype-specific drug response, which is expected to lead to development of tailored, precision care of the patients with hepatocellular carcinoma.

참고문헌 (Reference)

1 Santoro A, "Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study" 14 : 55-63, 2013

2 Giannelli G, "The rationale for targeting TGF-beta in chronic liver diseases" 46 : 349-361, 2016

3 Aird F, "Reproducibility Project: Cancer B, Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc" 6 : 2017

4 Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial" 16 : 859-870, 2015

5 Nagamori S, "Protein secretion of human cultured liver cells" 1 : 382-390, 1988

6 Huh N, "Production of HBs-antigen by two new human hepatoma cell lines and its enhancement by dexamethasone" 72 : 178-179, 1981

7 Hoshida Y, "Nearest Template Prediction: a single-sample-based flexible class prediction with confidence assessment" 5 : e15543-, 2010

8 Finn RS, "Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro" 57 : 1838-1846, 2013

9 Schmidt B, "Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition" 138 : 1494-1505, 2016

10 Goossens N, "Molecular classification of hepatocellular carcinoma: potential therapeutic implications" 2 : 371-379, 2015

11 Brunet JP, "Metagenes and molecular pattern discovery using matrix factorization" 101 : 4164-4169, 2004

12 Ikeda M, "Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma" 105 : 455-462, 2014

13 Hoshida Y, "Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma" 69 : 7385-7392, 2009

14 Knowles BB, "Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen" 209 : 497-499, 1980

15 Lopez-Terrada D, "Hep G2 is a hepatoblastoma-derived cell line" 40 : 1512-1515, 2009

16 Rebouissou S, "Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression" 64 : 2047-2061, 2016

17 Deshmukh M, "Genomic profiling of cell lines for personalized targeted therapy for hepatocellular carcinoma" 58 : 2207-, 2013

18 Lee JS, "Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer" 35 : 1134-1143, 2002

19 Zhu AX, "First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma" 19 : 920-928, 2013

20 Shibata T, "Exploration of liver cancer genomes" 11 : 340-349, 2014

21 Alexander JJ, "Establishment of a continuously growing cell line from primary carcinoma of the liver" 50 : 2124-2128, 1976

22 Dor I, "Establishment and some biological characteristics of human hepatoma cell lines" 66 : 385-392, 1975

23 Lee JH, "Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA" 5 : 289-295, 1999

24 Homma S, "Establishment and characterization of a human hepatocellular carcinoma cell line JHH-7 producing alpha-fetoprotein and carcinoembryonic antigen-changes in secretion of AFP and CEA from JHH-7 cells after heat treatment" 3 : 152-157, 1990

25 Hasumura S, "Establishment and characterization of a human hepatocellular carcinoma cell line JHH-4" 1 : 98-100, 1988

26 Hong Y, "Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma" 59 : 1448-1458, 2014

27 Fuchs BC, "Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells" 68 : 2391-2399, 2008

28 Zhao H, "Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/ IR inhibitor OSI-906 in hepatocellular carcinoma cell lines" 11 : 503-513, 2012

29 Eirew P, "Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution" 518 : 422-426, 2015

30 Bouhaddou M, "Drug response consistency in CCLE and CGP" 540 : E9-E10, 2016

31 Tan PS, "Clinicopathological indices to predict hepatocellular carcinoma molecular classification" 36 : 108-118, 2016

32 Park JG, "Characterization of cell lines established from human hepatocellular carcinoma" 62 : 276-282, 1995

33 Gao Q, "Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents" 152 : 232-242, 2017

34 Delmore JE, "BET bromodomain inhibition as a therapeutic strategy to target c-Myc" 146 : 904-917, 2011

35 Boehm JS, "An ecosystem of cancer cell line factories to support a cancer dependency map" 16 : 373-374, 2015

36 Kawai HF, "Alpha-fetoproteinproducing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis" 33 : 676-691, 2001

37 Mace K, "Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines" 18 : 1291-1297, 1997